| William D Ketcham, MD | |
|
800 E 20th St, Suite 110, Cheyenne, WY 82001-3859 | |
| (307) 634-7711 | |
| Not Available |
| Full Name | William D Ketcham |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 28 Years |
| Location | 800 E 20th St, Cheyenne, Wyoming |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184668857 | NPI | - | NPPES |
| 311699 | Other | WY | BCBS OF WYOMING CRG |
| 22971211 | Medicaid | CO | |
| 311700 | Other | WY | BCBS OF WYOMING MRI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 6803A (Wyoming) | Primary |
| 2085R0202X | Radiology - Diagnostic Radiology | 40972 (Colorado) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Cheyenne Regional Medical Center | Cheyenne, WY | Hospital |
| Wray Community District Hospital | Wray, CO | Hospital |
| Melissa Memorial Hospital | Holyoke, CO | Hospital |
| Sedgwick County Memorial Hospital | Julesburg, CO | Hospital |
| Platte County Memorial Hospital | Wheatland, WY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cheyenne Mri Llc | 6507756798 | 6 |
| Cheyenne Radiology Group | 1951293844 | 27 |
| Cwip Llc | 0840588752 | 6 |
News Archive
The last study participant has been recruited to Diamyd Medical's Phase II study in which cancer pain is treated with the drug candidate NP2 Enkephalin. The study is thus fully enrolled and results are expected to be reported in five to seven weeks.
Bayer HealthCare Pharmaceuticals announced today that RECOTHROM(R) (Thrombin alfa (Recombinant)), the first recombinant, plasma-free thrombin approved by Health Canada, is now available for use as a topical hemostatic solution. According to a recent clinical study, RECOTHROM(R) was found to successfully stop 80 per cent of surgical bleeding within three minutes and 95 per cent of bleeding within 10 minutes.
One key goal of treating pancreatic cancer, which is often fatal within a year, is making sure patients have a good quality of life with as few complications as possible. This is especially important if they are candidates for surgical removal of the cancer.
Genzyme Corporation announced today that it was included on both the 2009 Dow Jones Sustainability World Index and North American Index. This marks the fifth consecutive year Genzyme has been named to the Dow Jones Sustainability North American Index and the first year the company has been named to the Dow Jones Sustainability World Index.
› Verified 3 days ago
| Entity Name | Cheyenne Mri Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689613572 PECOS PAC ID: 6507756798 Enrollment ID: O20040319000673 |
News Archive
The last study participant has been recruited to Diamyd Medical's Phase II study in which cancer pain is treated with the drug candidate NP2 Enkephalin. The study is thus fully enrolled and results are expected to be reported in five to seven weeks.
Bayer HealthCare Pharmaceuticals announced today that RECOTHROM(R) (Thrombin alfa (Recombinant)), the first recombinant, plasma-free thrombin approved by Health Canada, is now available for use as a topical hemostatic solution. According to a recent clinical study, RECOTHROM(R) was found to successfully stop 80 per cent of surgical bleeding within three minutes and 95 per cent of bleeding within 10 minutes.
One key goal of treating pancreatic cancer, which is often fatal within a year, is making sure patients have a good quality of life with as few complications as possible. This is especially important if they are candidates for surgical removal of the cancer.
Genzyme Corporation announced today that it was included on both the 2009 Dow Jones Sustainability World Index and North American Index. This marks the fifth consecutive year Genzyme has been named to the Dow Jones Sustainability North American Index and the first year the company has been named to the Dow Jones Sustainability World Index.
› Verified 3 days ago
| Entity Name | Cheyenne Radiology Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023056082 PECOS PAC ID: 1951293844 Enrollment ID: O20040607000625 |
News Archive
The last study participant has been recruited to Diamyd Medical's Phase II study in which cancer pain is treated with the drug candidate NP2 Enkephalin. The study is thus fully enrolled and results are expected to be reported in five to seven weeks.
Bayer HealthCare Pharmaceuticals announced today that RECOTHROM(R) (Thrombin alfa (Recombinant)), the first recombinant, plasma-free thrombin approved by Health Canada, is now available for use as a topical hemostatic solution. According to a recent clinical study, RECOTHROM(R) was found to successfully stop 80 per cent of surgical bleeding within three minutes and 95 per cent of bleeding within 10 minutes.
One key goal of treating pancreatic cancer, which is often fatal within a year, is making sure patients have a good quality of life with as few complications as possible. This is especially important if they are candidates for surgical removal of the cancer.
Genzyme Corporation announced today that it was included on both the 2009 Dow Jones Sustainability World Index and North American Index. This marks the fifth consecutive year Genzyme has been named to the Dow Jones Sustainability North American Index and the first year the company has been named to the Dow Jones Sustainability World Index.
› Verified 3 days ago
| Entity Name | Cwip Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154774529 PECOS PAC ID: 0840588752 Enrollment ID: O20161010000699 |
News Archive
The last study participant has been recruited to Diamyd Medical's Phase II study in which cancer pain is treated with the drug candidate NP2 Enkephalin. The study is thus fully enrolled and results are expected to be reported in five to seven weeks.
Bayer HealthCare Pharmaceuticals announced today that RECOTHROM(R) (Thrombin alfa (Recombinant)), the first recombinant, plasma-free thrombin approved by Health Canada, is now available for use as a topical hemostatic solution. According to a recent clinical study, RECOTHROM(R) was found to successfully stop 80 per cent of surgical bleeding within three minutes and 95 per cent of bleeding within 10 minutes.
One key goal of treating pancreatic cancer, which is often fatal within a year, is making sure patients have a good quality of life with as few complications as possible. This is especially important if they are candidates for surgical removal of the cancer.
Genzyme Corporation announced today that it was included on both the 2009 Dow Jones Sustainability World Index and North American Index. This marks the fifth consecutive year Genzyme has been named to the Dow Jones Sustainability North American Index and the first year the company has been named to the Dow Jones Sustainability World Index.
› Verified 3 days ago
| Entity Name | University Hospitals Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669499414 PECOS PAC ID: 4789682493 Enrollment ID: O20170728003323 |
News Archive
The last study participant has been recruited to Diamyd Medical's Phase II study in which cancer pain is treated with the drug candidate NP2 Enkephalin. The study is thus fully enrolled and results are expected to be reported in five to seven weeks.
Bayer HealthCare Pharmaceuticals announced today that RECOTHROM(R) (Thrombin alfa (Recombinant)), the first recombinant, plasma-free thrombin approved by Health Canada, is now available for use as a topical hemostatic solution. According to a recent clinical study, RECOTHROM(R) was found to successfully stop 80 per cent of surgical bleeding within three minutes and 95 per cent of bleeding within 10 minutes.
One key goal of treating pancreatic cancer, which is often fatal within a year, is making sure patients have a good quality of life with as few complications as possible. This is especially important if they are candidates for surgical removal of the cancer.
Genzyme Corporation announced today that it was included on both the 2009 Dow Jones Sustainability World Index and North American Index. This marks the fifth consecutive year Genzyme has been named to the Dow Jones Sustainability North American Index and the first year the company has been named to the Dow Jones Sustainability World Index.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| William D Ketcham, MD 800 E 20th St, Suite 110, Cheyenne, WY 82001-3859 Ph: (307) 634-7711 | William D Ketcham, MD 800 E 20th St, Suite 110, Cheyenne, WY 82001-3859 Ph: (307) 634-7711 |
News Archive
The last study participant has been recruited to Diamyd Medical's Phase II study in which cancer pain is treated with the drug candidate NP2 Enkephalin. The study is thus fully enrolled and results are expected to be reported in five to seven weeks.
Bayer HealthCare Pharmaceuticals announced today that RECOTHROM(R) (Thrombin alfa (Recombinant)), the first recombinant, plasma-free thrombin approved by Health Canada, is now available for use as a topical hemostatic solution. According to a recent clinical study, RECOTHROM(R) was found to successfully stop 80 per cent of surgical bleeding within three minutes and 95 per cent of bleeding within 10 minutes.
One key goal of treating pancreatic cancer, which is often fatal within a year, is making sure patients have a good quality of life with as few complications as possible. This is especially important if they are candidates for surgical removal of the cancer.
Genzyme Corporation announced today that it was included on both the 2009 Dow Jones Sustainability World Index and North American Index. This marks the fifth consecutive year Genzyme has been named to the Dow Jones Sustainability North American Index and the first year the company has been named to the Dow Jones Sustainability World Index.
› Verified 3 days ago
Don R Dickerson, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 214 E 23rd St, Cheyenne, WY 82001 Phone: 307-633-7823 Fax: 307-633-7818 | |
James G Hubbard, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 800 E 20th St, Suite 110, Cheyenne, WY 82001 Phone: 307-634-7711 | |
Eric Richard Hoyer, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 2003 Bluegrass Circle, Cheyenne, WY 82009 Phone: 307-634-7711 | |
Subashini T Furman, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 310 E 24th St, Cheyenne, WY 82001 Phone: 307-634-9311 Fax: 307-634-5627 | |
Mrs. Sarah Elizabeth Matney, RT (R) (CT) Radiology Medicare: Not Enrolled in Medicare Practice Location: 214 E 23rd St, Cheyenne, WY 82001 Phone: 307-634-7800 | |
Dr. Jeffrey C Carlton, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 214 E 23rd St, Cheyenne, WY 82001 Phone: 307-633-7823 Fax: 307-633-7818 |